The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

This was the stock's second consecutive day of gains.

Regeneron is hoping a new program will widen patient access to its eye drug without also benefiting the company's rivals — a ...

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a study titled ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

Retirement Systems of Alabama made a bold financial move by increasing its stake in Regeneron Pharmaceuticals by a whopping ...

The combination offers a potential solution to one of the key problems that’s emerged with popular obesity shots.

UBS has decided Regeneron Pharmaceuticals needs a new wardrobe, trimming its price target from $633 to a more modest $560.

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

As the global weight-loss market explodes, drugmakers are now racing to solve a less visible problem: protecting muscle mass ...